Utomilumab, previously known as PF-2566, represents a intriguing clinical avenue in inflammatory disorders. This engineered antibody specifically blocks the function of the – a critical receptor involved in antibody-dependent cellular activity. Early research indicates substantial efficacy in reducing symptom severity, particularly within the co… Read More